Advances in the design and development of chemical modulators of the voltage-gated potassium channels KV7.4 and KV7.5.

IF 6 2区 医学 Q1 PHARMACOLOGY & PHARMACY
Expert Opinion on Drug Discovery Pub Date : 2025-01-01 Epub Date: 2024-12-09 DOI:10.1080/17460441.2024.2438226
Jana Lemke, Maik Gollasch, Dmitry Tsvetkov, Lukas Schulig
{"title":"Advances in the design and development of chemical modulators of the voltage-gated potassium channels K<sub>V</sub>7.4 and K<sub>V</sub>7.5.","authors":"Jana Lemke, Maik Gollasch, Dmitry Tsvetkov, Lukas Schulig","doi":"10.1080/17460441.2024.2438226","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Hypertension remains a major public health concern, with significant morbidity and mortality worldwide. Despite the availability of various antihypertensive medications, blood pressure control remains suboptimal in many individuals. During the last decades, K<sub>V</sub>7.4 and K<sub>V</sub>7.5, which were already known from the view of neuronal regulation, emerged as possible important players in the regulation of vascular tone and blood pressure.</p><p><strong>Areas covered: </strong>This review covers physiological functions and current advancements in the development of K<sub>V</sub>7.4 and K<sub>V</sub>7.5 channel modulators. The authors highlight the structural elements likely to be important for the future design of K<sub>V</sub>7 subtype-selective modulators, underscoring their potential as an innovative hypertension treatment.</p><p><strong>Expert opinion: </strong>Extensive research has been focused on targeting neuronal K<sub>V</sub>7.2 and K<sub>V</sub>7.3 channels, while K<sub>V</sub>7.4 and K<sub>V</sub>7.5 attracted less attention. Many of the developed compounds represent derivatives of flupirtine or retigabine, whereby subtype channel selectivity has only been demonstrated for a handful of individual compounds. Novel substances address additional sites within the binding pocket by incorporating new functional groups. A comprehensive and systematic evaluation of a compound set with significant subtype selectivity should be performed. The discovery of new highly active, less toxic, and selective compounds, therefore, remains the goal of further research in the coming years.</p>","PeriodicalId":12267,"journal":{"name":"Expert Opinion on Drug Discovery","volume":" ","pages":"47-62"},"PeriodicalIF":6.0000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Opinion on Drug Discovery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17460441.2024.2438226","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/12/9 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Hypertension remains a major public health concern, with significant morbidity and mortality worldwide. Despite the availability of various antihypertensive medications, blood pressure control remains suboptimal in many individuals. During the last decades, KV7.4 and KV7.5, which were already known from the view of neuronal regulation, emerged as possible important players in the regulation of vascular tone and blood pressure.

Areas covered: This review covers physiological functions and current advancements in the development of KV7.4 and KV7.5 channel modulators. The authors highlight the structural elements likely to be important for the future design of KV7 subtype-selective modulators, underscoring their potential as an innovative hypertension treatment.

Expert opinion: Extensive research has been focused on targeting neuronal KV7.2 and KV7.3 channels, while KV7.4 and KV7.5 attracted less attention. Many of the developed compounds represent derivatives of flupirtine or retigabine, whereby subtype channel selectivity has only been demonstrated for a handful of individual compounds. Novel substances address additional sites within the binding pocket by incorporating new functional groups. A comprehensive and systematic evaluation of a compound set with significant subtype selectivity should be performed. The discovery of new highly active, less toxic, and selective compounds, therefore, remains the goal of further research in the coming years.

电压门控钾通道KV.4和KV.5化学调节剂的设计与研制进展。
高血压仍然是一个主要的公共卫生问题,在世界范围内具有显著的发病率和死亡率。尽管有各种降压药物,但许多人的血压控制仍不理想。在过去的几十年里,KV7.4和KV7.5已经从神经元调节的角度被发现,可能在血管张力和血压的调节中发挥重要作用。涵盖领域:本文综述了KV7.4和KV7.5通道调节剂的生理功能和目前的发展进展。作者强调了结构元素可能对kv7亚型选择性调节剂的未来设计很重要,强调了它们作为创新高血压治疗的潜力。专家意见:针对神经元KV7.2和KV7.3通道的研究较多,而KV7.4和KV7.5通道的研究较少。许多已开发的化合物代表氟吡汀或瑞gabine的衍生物,因此亚型通道选择性仅被证明为少数单个化合物。新物质通过结合新的官能团来处理结合口袋内的附加位点。应该对具有显著亚型选择性的化合物集进行全面和系统的评估。因此,发现新的高活性、低毒性和选择性的化合物仍然是未来几年进一步研究的目标。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
10.20
自引率
1.60%
发文量
78
审稿时长
6-12 weeks
期刊介绍: Expert Opinion on Drug Discovery (ISSN 1746-0441 [print], 1746-045X [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles on novel technologies involved in the drug discovery process, leading to new leads and reduced attrition rates. Each article is structured to incorporate the author’s own expert opinion on the scope for future development. The Editors welcome: Reviews covering chemoinformatics; bioinformatics; assay development; novel screening technologies; in vitro/in vivo models; structure-based drug design; systems biology Drug Case Histories examining the steps involved in the preclinical and clinical development of a particular drug The audience consists of scientists and managers in the healthcare and pharmaceutical industry, academic pharmaceutical scientists and other closely related professionals looking to enhance the success of their drug candidates through optimisation at the preclinical level.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信